Literature DB >> 8423274

The evidence of platelet activation in bronchial asthma.

H Yamamoto1, M Nagata, K Tabe, I Kimura, H Kiuchi, Y Sakamoto, K Yamamoto, Y Dohi.   

Abstract

The possible involvement of platelets in bronchial asthma was investigated under three different conditions: (1) chronic asthma, (2) bronchial provocation inhaling house dust mite (HDM), and (3) status asthmaticus. Plasma levels of beta-thromboglobulin (beta-TG), platelet factor 4 (PF4), and in part, platelet-activating factor (PAF) were measured. Approximately one third of the subjects with symptomatic or asymptomatic chronic asthma showed an increased level of beta-TG or PF4. Statistically significant differences occurred in beta-TG and PF4 levels only between healthy controls and symptomatic subjects. Five out of six subjects showed no elevation of beta-TG and PF4 during immediate asthmatic response. In two out of nine subjects with status asthmaticus, beta-TG or PF4 was elevated, and statistically significant correlations occurred between the initial level of PAF and that of beta-TG or PF4. Those results suggest that the platelet activation in the circulation is sometimes provoked in asthma, but plasma level of alpha-granule-derived proteins does not reflect the intensity or severity of asthma, and that PAF is likely to be a mediator responsible for the platelet activation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8423274     DOI: 10.1016/0091-6749(93)90299-u

Source DB:  PubMed          Journal:  J Allergy Clin Immunol        ISSN: 0091-6749            Impact factor:   10.793


  10 in total

1.  Enhanced platelet activation in patients with atopic eczema/dermatitis syndrome.

Authors:  Alicja Kasperska-Zajac; Marek Nowakowski; Barbara Rogala
Journal:  Inflammation       Date:  2004-10       Impact factor: 4.092

2.  Airway platelet activation is associated with airway eosinophilic inflammation in asthma.

Authors:  Angela S Benton; Nikila Kumar; Jennifer Lerner; Andrew A Wiles; Matthew Foerster; Stephen J Teach; Robert J Freishtat
Journal:  J Investig Med       Date:  2010-12       Impact factor: 2.895

3.  Platelets promote allergic asthma through the expression of CD154.

Authors:  Jun Tian; Tianyi Zhu; Juan Liu; Zhenhong Guo; Xuetao Cao
Journal:  Cell Mol Immunol       Date:  2014-11-24       Impact factor: 11.530

Review 4.  Platelet activation during allergic inflammation.

Authors:  Alicja Kasperska-Zajac; Barbara Rogala
Journal:  Inflammation       Date:  2007-10       Impact factor: 4.092

Review 5.  Platelet activating factor as a mediator and therapeutic approach in bronchial asthma.

Authors:  A Kasperska-Zajac; Z Brzoza; B Rogala
Journal:  Inflammation       Date:  2008-01-12       Impact factor: 4.092

Review 6.  Chronic Rhinosinusitis and the Coagulation System.

Authors:  Dong Young Kim; Seong H Cho; Tetsuji Takabayashi; Robert P Schleimer
Journal:  Allergy Asthma Immunol Res       Date:  2015-05-12       Impact factor: 5.764

7.  The synergistic effects of clopidogrel with montelukast may be beneficial for asthma treatment.

Authors:  Hoang Kim Tu Trinh; Thuy Van Thao Nguyen; Youngwoo Choi; Hae-Sim Park; Yoo Seob Shin
Journal:  J Cell Mol Med       Date:  2019-03-23       Impact factor: 5.310

8.  Characterisation of P2Y(12) receptor responsiveness to cysteinyl leukotrienes.

Authors:  Holly R Foster; Elisabeth Fuerst; Tak H Lee; Davis J Cousins; Grzegorz Woszczek
Journal:  PLoS One       Date:  2013-03-05       Impact factor: 3.240

9.  Can mean platelet volume be used as a biomarker for asthma?

Authors:  Hikmet Tekin Nacaroglu; Rana Isguder; Semiha Erdem Bahceci; Gökhan Ceylan; Huseyin Anil Korkmaz; Sait Karaman; Canan Sule Unsal Karkıner; Demet Can
Journal:  Postepy Dermatol Alergol       Date:  2016-06-17       Impact factor: 1.837

10.  Can mean platelet volume and neutrophil-to-lymphocyte ratio be biomarkers of acute exacerbation of bronchiectasis in children?

Authors:  Hikmet T Nacaroglu; Semiha Bahceci Erdem; Sait Karaman; Selcuk Yazici; Demet Can
Journal:  Cent Eur J Immunol       Date:  2017-12-30       Impact factor: 2.085

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.